The approval stipulates use in advanced, unresectable, or metastatic disease that progressed on prior systemic therapy.
The U.S. Food and Drug Administration has approved Merus NV's therapy that targets a particular gene, expanding treatment ...
The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.
When it comes to cancer, aging is a double-edged sword, researchers are increasingly learning. Age is considered the most ...
When it comes to cancer, aging is a double-edged sword, researchers are increasingly learning. Age is considered the most important risk factor for cancer. That's because genetic mutations build up in ...
A new method can improve treatment for patients with chronic myeloid leukemia by predicting which medication will be most ...
A new method can improve treatment for patients with chronic myeloid leukaemia by predicting which medication will be most effective. The method also works for other forms of cancer where resistance ...
highlighted the growing role of biomarker-driven therapies in non–small cell lung cancer (NSCLC), noting ongoing research to apply these treatments in earlier stages and to target currently ...
The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...
Merck's (MRK) antibody drug conjugate sac-TMT has received FDA Breakthrough Therapy designation for the treatment of EGFR-mutated lung cancer. Read more here.
1d
Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...
Oct. 9, 2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 ... Scientists Discover That ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback